创新试验台，使生态系统推动纳米药物推向市场。

IF 7.5 2区医学 Q1 PHARMACOLOGY & PHARMACY

Drug Discovery Today Pub Date : 2025-07-15 DOI:10.1016/j.drudis.2025.104433

Luis Padrela , Rabah Mouras , Donal Killackey

{"title":"创新试验台，使生态系统推动纳米药物推向市场。","authors":"Luis Padrela , Rabah Mouras , Donal Killackey","doi":"10.1016/j.drudis.2025.104433","DOIUrl":null,"url":null,"abstract":"<div><div>It is a major challenge to produce proof-of-concept (PoC) pharmaceutical nanoformulations of the required quality level, and in sufficient quantities for late preclinical and clinical testing. The creation of bespoke capabilities to assist in the translation of early stage PoC medicines could greatly reduce time and cost to bring new and innovative therapies to the market. This paper reflects on current barriers hampering the commercialization of novel nanopharmaceuticals and discusses the potential for integrated approaches to bring together existing and new processing infrastructures to de-risk and accelerate the development, manufacturing and market entry of the next-generation nanopharmaceuticals.</div></div>","PeriodicalId":301,"journal":{"name":"Drug Discovery Today","volume":"30 8","pages":"Article 104433"},"PeriodicalIF":7.5000,"publicationDate":"2025-07-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Innovation testbeds as enabling ecosystems driving nanopharmaceuticals to market\",\"authors\":\"Luis Padrela , Rabah Mouras , Donal Killackey\",\"doi\":\"10.1016/j.drudis.2025.104433\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<div><div>It is a major challenge to produce proof-of-concept (PoC) pharmaceutical nanoformulations of the required quality level, and in sufficient quantities for late preclinical and clinical testing. The creation of bespoke capabilities to assist in the translation of early stage PoC medicines could greatly reduce time and cost to bring new and innovative therapies to the market. This paper reflects on current barriers hampering the commercialization of novel nanopharmaceuticals and discusses the potential for integrated approaches to bring together existing and new processing infrastructures to de-risk and accelerate the development, manufacturing and market entry of the next-generation nanopharmaceuticals.</div></div>\",\"PeriodicalId\":301,\"journal\":{\"name\":\"Drug Discovery Today\",\"volume\":\"30 8\",\"pages\":\"Article 104433\"},\"PeriodicalIF\":7.5000,\"publicationDate\":\"2025-07-15\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Drug Discovery Today\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://www.sciencedirect.com/science/article/pii/S1359644625001461\",\"RegionNum\":2,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q1\",\"JCRName\":\"PHARMACOLOGY & PHARMACY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Drug Discovery Today","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S1359644625001461","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"PHARMACOLOGY & PHARMACY","Score":null,"Total":0}

引用次数: 0

摘要

生产具有所需质量水平和足够数量的概念验证（PoC）药物纳米制剂用于后期临床前和临床试验是一项重大挑战。创建定制能力以协助翻译早期PoC药物可以大大减少将新的创新疗法推向市场的时间和成本。这篇论文反映了当前阻碍新型纳米药物商业化的障碍，并讨论了整合方法的潜力，将现有的和新的加工基础设施结合起来，以降低风险并加速下一代纳米药物的开发、制造和市场进入。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

Innovation testbeds as enabling ecosystems driving nanopharmaceuticals to market

查看原文本刊更多论文

Innovation testbeds as enabling ecosystems driving nanopharmaceuticals to market

It is a major challenge to produce proof-of-concept (PoC) pharmaceutical nanoformulations of the required quality level, and in sufficient quantities for late preclinical and clinical testing. The creation of bespoke capabilities to assist in the translation of early stage PoC medicines could greatly reduce time and cost to bring new and innovative therapies to the market. This paper reflects on current barriers hampering the commercialization of novel nanopharmaceuticals and discusses the potential for integrated approaches to bring together existing and new processing infrastructures to de-risk and accelerate the development, manufacturing and market entry of the next-generation nanopharmaceuticals.

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

Drug Discovery Today 医学-药学

CiteScore

14.80

自引率

2.70%

发文量

293

审稿时长

6 months

期刊介绍： Drug Discovery Today delivers informed and highly current reviews for the discovery community. The magazine addresses not only the rapid scientific developments in drug discovery associated technologies but also the management, commercial and regulatory issues that increasingly play a part in how R&D is planned, structured and executed. Features include comment by international experts, news and analysis of important developments, reviews of key scientific and strategic issues, overviews of recent progress in specific therapeutic areas and conference reports.